Cardea raises $7.8 million for graphene-based biosensors

March 26, 2019
Accelerating Materials Innovation More...
Average importance

Biosensors are one of the main applications for graphene thin films, bur startups like Graphene Frontiers have failed to make much commercial headway. Cardea (formerly Nanomaterial Diagnostics) has a more robust supply chain than most players in this space, and this funding is a good sign of momentum. Still, clients should only monitor until Cardea validates the value proposition of its sensors with sales or partnerships.

For the original news article, click here .

Further Reading

Directa Plus

Company Profile | November 10, 2020

Produces graphene nanoplatelets (GNPs) by chemical intercalation of natural graphite followed by thermal plasma exfoliation; sells powder and water dispersion products Operates a 30 ton/yr GNP production facility since 2014 Joint development agreements (JDAs) with a handful of industry ... Not part of subscription

Cardea continues to raise funds for graphene sensors with $7.5 million round

News Commentary | September 18, 2020

Caredea has raised around $15 million in the past two years. While it is heartening to see some momentum around advanced graphene electronics, there's a distinct lack of diversity in the space, with Cardea and Paragraf getting nearly all the attention. Clients should recognize that the number of ... Not part of subscription

HeiQ now public on London Stock Exchange

News Commentary | December 09, 2020

HeiQ, a developer of functional textile materials and finishings – notably for its HeiQ Viroblock coating that claims to be effective against SARS‑CoV‑2 – is now a publicly listed company on the London Stock Exchange, raising $80 million in the IPO. This shift to the public market will further the ... Not part of subscription